FDA approved mFlusiva — the first mRNA influenza vaccine — for adults ages 50–64, marking a regulatory milestone. CDC has not recommended the shot this season, citing “legal uncertainties and inquiries,” so mFlusiva is not on the agency’s official list for fall immunization. Medical societies recommend it as an option while federal advisory processes remain unsettled. Experts say political disputes and litigation have interrupted the usual pipeline that turns approvals into clear public guidance.
FDA Clears First mRNA Flu Vaccine mFlusiva for Ages 50–64 — CDC Has Not Endorsed It
Lead medical assistant Yiseli Dominguez administers a flu vaccine to a patient at the Esperanza Health Centers Brighton Park North Clinic, Dec. 31, 2025, in Chicago. (Eileen T. Meslar/Chicago Tribune/Tribune News Service via Getty Images)
The Food and Drug Administration has granted full approval to mFlusiva, the first influenza vaccine developed with mRNA technology, for use in adults ages 50 to 64. While the regulatory milestone validates the vaccine’s safety and efficacy data for that age group, federal public-health guidance on its use has not yet been finalized.
What Happened
The FDA’s approval follows clinical trials showing favorable results in older adults. However, the Centers for Disease Control and Prevention (CDC) has not added mFlusiva to this season’s list of recommended flu vaccines. In a brief public notice, CDC officials said they would continue last year’s flu vaccine endorsements while they address “legal uncertainties and inquiries,” effectively leaving mFlusiva off the agency’s official recommendations for the coming fall.
Medical Groups, Clinicians and the Public
Professional medical societies and other clinical groups are advising that mFlusiva may be offered as an option to eligible patients ages 50–64. Those organizations note the vaccine performed well in clinical testing and can be considered by clinicians while federal advisory processes are unsettled.
Why Guidance Is Delayed
Experts say political disputes and litigation have disrupted the usual flow that converts FDA approvals into clear public-health recommendations. The article cites efforts by vaccine-skeptical officials associated with the prior Trump administration and recent actions by Health Secretary Robert F. Kennedy Jr. — including public criticism of mRNA vaccines and contract cancellations — as contributing factors to the current uncertainty. Legal challenges and internal reviews have also slowed advisory committees and decisionmaking.
“We find ourselves at a point where even if credible evidence for a new vaccine policy has reached a tipping point, we don't have an obvious mechanism that can formalize that change,” said Jason Schwartz, a Yale University health policy researcher who studies government health agencies.
Broader Effects
The delay in CDC recommendations has affected other federal vaccine programs as well. Officials postponed clarity about whether updated COVID-19 vaccines would be covered by the Vaccines for Children (VFC) program; federal authorities only recently confirmed that orders for those updated shots could be placed through VFC. Observers warn that stalled guidance can create confusion for clinicians, insurers and patients planning fall vaccination campaigns.
What Patients and Clinicians Should Do
Adults ages 50–64 who are interested in mFlusiva should talk with their health care provider about available options and individual risk factors. Clinicians should monitor updates from the FDA and CDC and consult statements from professional societies when making recommendations. Because mFlusiva is FDA-approved but not yet on the CDC’s recommended list, coverage and official program inclusion may vary until agencies resolve outstanding questions.
Sources: FDA approval documents, CDC public postings, statements from medical organizations, reporting by The Associated Press, and commentary from Yale health policy researcher Jason Schwartz.
Help us improve.
